BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:LNPs continue to dominate as the non-viral delivery vehicle of choice given their ability to encapsulate fragile payloads\, such as mRN A\, siRNA\, gRNA and more\, and deliver them into target cells with high efficacy. However\, critical challenges remain in assessing targeted LNP surface functionalization\, evaluating encapsulation efficiency for multi valent formulations\, and aligning analytical results with process perfor mance.\n\nThe 3rd LNP Characterization and Analytical Development Summit is the only global event dedicated to this specialized field\, providing analytical experts with in-depth technical insights into accelerating dev elopment timelines\, overcoming analytical gaps and streamlining regulato ry submissions for fast-tracking approval of high-quality LNP drug produc ts.\n\nJoin experts from Pfizer\, Novo Nordisk\, Prime Medicine\, Tessera Therapeutics\, GSK\, Sanofi\, and more as we explore the cutting edge of LNP characterization and analytics. Don’t miss this opportunity to colla borate with the brightest minds shaping the future of LNP drug developmen t.\n\nURLs:Tickets: \;https://go.evvnt.com/3169531-2?pid=185 \;Br ochure: \;https://go.evvnt.com/3169531-3?pid=185 \;\n\nDate and T ime: Tue\, 18 Nov 2025 07:30 - Thu\, 20 Nov 2025 16:30\n\nVenue details: Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, Massachuset ts\, 02128\, United States\n\nPrices:Conference Only - Drug Developer: US D 2999.00\,Conference Only - Solution Provider: USD 3699.00\,Conference O nly - Academics: USD 2599.00\,Conference + Workshop Day - Drug Developer: USD 4197.00\,Conference + Workshop Day - Solution Provider: USD 5097.00\ ,Conference + Workshop Day - Academics: USD 3597.00\n\nSpeakers: Jean-Luc Fraikin\, Chief Executive Officer\, Spectradyne LLC\, Kan Zhu\, Director \, Head of Analytical Biochemistry\, CSL\, Mohit Gupta\, Principal Scient ist\, Tessera Therapeutics\, Justin Fang\, Senior Scientist\, RNA NewCo\, Elias Halabi\, Senior Scientist II\, Novo Nordisk\, Wei-Chiang Chen\, As sociate Director\, Sanofi\, Zack Zhang\, Director - Analytical Developmen t\, Beam Therapeutics Inc.\, Dandan Ling\, Director\, Formulation Researc h and Development\, Suzhou Aibo Biotechnology Co.\, Ltd.\, Pushkar Saralk ar\, Senior Scientist\, Pfizer\, Ruchi Shah\, Director\, Drug Product\, V accines Technical Research and Development\, GSK US\, Ramsey Majzoub\, Di rector\, Intellia Therapeutics\, Sanjib Saha\, Senior Scientist\, AstraZe neca\, John Haserick\, Director\, Analytical Research and Development\, G laxoSmithKline\, Navid Bizmark\, Materials Characterization Team Lead - S enior Principal Scientist\, Pfizer\, Jeffrey Clogston\, Principal Scienti st and Head of Physicochemical Characterization Section\, National Cancer Institute\, Shashank Shukla\, Senior Scientist II\, Abbvie\, Baixue (Dor othy) Xiao\, Postdoctoral Fellow\, Genentech\, Kala Dasuri\, CMC\, Sanofi \, Minjia Wang\, Scientist II\, Analytical Development\, Prime Medicine\, Qook Lee\, Research Advisor\, Eli Lilly and Co.\, Stephan Stern\, Direct or\, Research and Development\, Nanotechnology Characterization Lab\, Can cer Research Technology Program\, Frederick National Laboratory for Cance r Research\, Sam Lai\, Professor\, Division of Pharmacoengineering and Mo lecular Pharmaceutics\, University of North Carolina - Chapel Hill\, Tong (Jenny) Liu\, Senior Principal Scientist\, United States Pharmacopeia\, Kanika Suri\, Scientist\, Takeda Pharmaceutical\, Jikang Wu\, Senior Prin cipal Scientist\, Regeneron Pharmaceuticals\n DTEND:20251120T163000 DTSTAMP:20260512T230907Z DTSTART:20251118T073000 LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive \, Boston\, M assachusetts\, 02128\, SEQUENCE:0 SUMMARY:LNPs continue to dominate as the non-viral delivery vehicle of cho ice given their ability to encapsulate fragile payloads\, such as mRNA\, siRNA\, gRN... UID:619a1fb7-ac7b-4b5c-9342-81a1d49277db END:VEVENT END:VCALENDAR